Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.

International journal of clinical pharmacology and therapeutics - 1 Feb 2009

Ma J D, Lawendy N M, Fullerton T, Snyder P J, Nafziger A N, Bertino J S

Abstract excerpt

UNLABELLED: Phenotyping intestinal and hepatic cytochrome P450 (CYP) 3A activity with oral midazolam can be limited by midazolam-induced central nervous system (CNS) side effects. Determining methods to minimize CNS side effects optimizes use of midazolam as a CYP3A probe. OBJECTIVE: The objective of this study was to determine the effect of intravenous (i.v.) flumazenil on midazolam apparent oral clearance (a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Double-Blind Method

Share to Drug Interactions

Share to Injections, Intravenous

Share to Maze Learning

Share to Midazolam

Source

Identifiers

PMID: 19203567
DOI: 10.5414/cpp47111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.PMID 19203567Read ↗

Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.Semantic proximity Read ↗

Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.Semantic proximity Read ↗

A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe.Semantic proximity Read ↗

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.Semantic proximity Read ↗

Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Semantic proximity Read ↗

Effect of breviscapine on CYP3A metabolic activity in healthy volunteers.Semantic proximity Read ↗

A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.Semantic proximity Read ↗

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.Semantic proximity Read ↗

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.Semantic proximity Read ↗

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.